RxDoctor Payments Data

Ramsis Olazagasti Ledee, MD

General Practice · Caguas, PRNPI 1801855994

Payments from drug & device makers

$309in general payments, 2019–2025

Across 12 payments — averaging $25.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$119
  • Hikma Pharmaceuticals USA$54
  • AstraZeneca$30
  • Pfizer$26
  • AbbVie$22
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$16
  • plus $42 from 3 others

What the payments were for

  • Food & beverage$28893%
  • Education$217%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$309 in reported general payments places this provider in the 60th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$82,112
Medicare patients
272
Services billed
775

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$39,971
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$26,174
JanuviaSitagliptin Phosphate39$24,524
XareltoRivaroxaban15$21,538
OzempicSemaglutide16$17,898
FarxigaDapagliflozin Propanediol14$11,764
JardianceEmpagliflozin13$10,652
Novolog FlexpenInsulin Aspart13$5,034
Atorvastatin Calcium373$4,317
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$4,104
PremarinEstrogens, Conjugated11$3,904
Levothyroxine Sodium274$3,058
SynthroidLevothyroxine Sodium25$2,559
Albuterol Sulfate HfaAlbuterol Sulfate72$2,455
Gabapentin141$2,435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$26$43,87556 claims
GSKTrelegy Ellipta$14$26,17431 claims
AstraZenecaFarxiga$30$11,76414 claims
AbbVieSynthroid$22$2,55925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Caguas

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →